NewcelX announces collaboration with Eledon Pharmaceuticals to advance Type 1 Diabetes therapy, NCEL-101, at the Swiss Biotech Conference.
Quiver AI Summary
NewcelX Ltd., a clinical-stage regenerative medicine company focused on stem-cell-derived therapies, announced the release of an updated corporate presentation showcasing its partnership with Eledon Pharmaceuticals. This collaboration aims to enhance NewcelX's Type 1 Diabetes program, NCEL-101, which utilizes a stem-cell-derived islet replacement platform integrated with Eledon's immune-modulation therapy, tegoprubart. NewcelX believes this approach could significantly improve graft survival and lead to a functional cure for Type 1 Diabetes. The company plans to discuss its ongoing strategy and development vision at the upcoming Swiss Biotech Conference, emphasizing its mission to address critical medical needs in diabetes treatment.
Potential Positives
- NewcelX's strategic collaboration with Eledon Pharmaceuticals highlights a significant partnership that could enhance the development of its Type 1 Diabetes program, NCEL-101.
- The integration of NewcelX’s stem-cell-derived islet replacement platform with Eledon’s immune-modulation therapy presents a promising strategy for improving graft survival and the potential for a functional cure for Type 1 Diabetes.
- The upcoming presentation at the Swiss Biotech Conference provides an opportunity for NewcelX to communicate its evolving development vision to investors and industry participants, potentially increasing visibility and interest in its innovative therapies.
Potential Negatives
- The press release heavily emphasizes forward-looking statements, which could be seen as a sign of uncertainty regarding the company's ability to achieve its goals and meet expectations.
- There is an acknowledgment of multiple uncertainties and risks that could materially affect the company's outcomes, potentially undermining investor confidence.
- The company does not undertake any obligation to update forward-looking statements, which may cause concerns among stakeholders about the transparency and accountability of the management's future projections.
FAQ
What is NewcelX Ltd. focusing on in their latest announcement?
NewcelX Ltd. is focusing on their collaboration with Eledon Pharmaceuticals and advancing their Type 1 Diabetes program, NCEL-101.
How does NCEL-101 aim to help with Type 1 Diabetes?
NCEL-101 is designed to restore functional insulin production through stem-cell-derived cell replacement therapy.
What is the role of Eledon Pharmaceuticals in the collaboration?
Eledon Pharmaceuticals provides the investigational anti-CD40L monoclonal antibody tegoprubart to prevent immune-mediated transplant rejection.
When will NewcelX present its updated strategy to investors?
NewcelX will present its evolving strategy at the upcoming Swiss Biotech Conference.
Where can I find more information about NewcelX Ltd.?
More information can be found on NewcelX's website at www.newcelx.com.
Disclaimer: This is an AI-generated summary of a press release distributed by GlobeNewswire. The model used to summarize this release may make mistakes. See the full release here.
$NCEL Hedge Fund Activity
We have seen 0 institutional investors add shares of $NCEL stock to their portfolio, and 0 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- CORECAP ADVISORS, LLC added 0 shares (+0.0%) to their portfolio in Q1 2026, for an estimated $0
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard.
Full Release
ZURICH, Switzerland, April 20, 2026 (GLOBE NEWSWIRE) -- NewcelX Ltd. (Nasdaq: NCEL),– NewcelX Ltd . (Nasdaq: NCEL), a clinical-stage regenerative medicine company developing stem-cell-derived therapies, today announced the release of an updated corporate presentation that includes the company’s strategic collaboration with Eledon Pharmaceuticals (Nasdaq: ELDN) and highlights the advancement of its flagship Type 1 Diabetes program, NCEL-101, as a central pillar of the company’s development strategy.
The updated presentation outlines the integration of NewcelX’s scalable stem-cell-derived islet replacement platform with Eledon’s investigational anti-CD40L monoclonal antibody tegoprubart, a targeted immune-modulation therapy designed to prevent immune-mediated transplant rejection. NewcelX believes this combined approach represents a promising strategy to support durable graft survival and advance the development of a potential functional cure for Type 1 Diabetes.
Management plans to present the updated presentation to investors and industry participants at the upcoming Swiss Biotech Conference, where NewcelX will present its evolving strategy and development vision for the Type 1 Diabetes program.
About NewcelX
NewcelX is an innovative biopharmaceutical company focused on developing transformative stem-cell-derived therapies for Type 1 Diabetes. Built on a validated human pluripotent stem cell (hPSC) platform, the company’s lead program, NCEL-101, is designed to restore functional insulin production through scalable, off-the-shelf cell replacement. NewcelX is advancing a comprehensive therapeutic approach for Type 1 Diabetes integrating cell therapy, immune protection, and translational science to address critical unmet medical needs.
Social Media: LinkedIn , Facebook , X , Instagram
Website: www.newcelx.com
Forward-Looking Statements
This press release contains expressed or implied forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 and other applicable securities laws. For example, NewcelX is using forward-looking statements when it discusses how the collaboration represents a promising strategy to support durable graft survival and advance the development of a potential functional cure for Type 1 Diabetes. These forward-looking statements and their implications are based on the current expectations of the management of NewcelX and are subject to a number of factors and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements. The following factors, among others, could cause actual results to differ materially from those described in the forward-looking statements: changes in technology and market requirements; potential delays or obstacles in launching or completing clinical trials; products that may not be approved by regulatory agencies; technologies that may not be validated or accepted by the scientific community; the inability to retain or attract key employees; unforeseen scientific difficulties with products in development; higher-than-expected product costs; results in the laboratory that do not translate to clinical success; insufficient patent protection; possible adverse safety outcomes; legislative changes; delays in developing or introducing new technologies, products, or applications; and competitive pressures that could reduce market share or pricing. Except as otherwise required by law, NewcelX does not undertake any obligation to publicly release revisions to these forward-looking statements to reflect events or circumstances after the date hereof or to reflect the occurrence of unanticipated events. More detailed information about the risks and uncertainties affecting the Company is contained under the heading "Risk Factors" in its Annual Report on Form 20-F for the year ended December 31, 2024, filed with the U.S. Securities and Exchange Commission ("SEC") and available at www.sec.gov , as well as in subsequent filings made by NewcelX, including under the heading "Risk Factors" in its proxy statement/prospectus filed with the SEC on November 6, 2025.
Investor & Media Contacts
Sarah Bazak, Investors relations
[email protected]
